X. Charlie Dong, Ph.D.
Department of Biochemistry and Molecular Biology
Indiana University School of Medicine
John D. Van Nuys Medical Science Building
635 Barnhill Drive, Room 1021D
Indianapolis, Indiana 46202-5126
Phone: (317) 278-1097
Facsimile: (317) 274-4686
B.S. in Biology, 1991, Shandong Normal University, Jinan, China
M.S. in Genetics, 1994, Institute of Genetics, Chinese Academy of Sciences, Beijing, China
Ph.D. in Molecular, Cellular, and Developmental Biology, 2002, Ohio State University, Columbus, OH
Postdoctoral fellow, 2003-2008, Harvard Medical School, Children's Hospital Boston, Joslin Diabetes Center, Boston, MA
Area of Study
Epigenetic and transcriptional regulation of metabolism, diabetes, obesity, diabetic complications, and fatty liver disease. More details...
Selected Recent Publications
Xiong X, Sun X, Wang Q, Qian X, Zhang Y, Pan X, Dong XC. SIRT6 protects against palmitate-induced pancreatic β-cell dysfunction and apoptosis. J Endocrinol. 2016 Sep 6. pii: JOE-16-0317. [Epub ahead of print]
Srivastava R, Zhang Y, Xiong X, Zhang X, Pan X, Dong XC, Liangpunsakul S, Janga SC. Prediction and Validation of Transcription Factors Modulating the Expression of Sestrin3 Gene Using an Integrated Computational and Experimental Approach. PLoS One. 2016 Jul 28;11(7):e0160228.
Klionsky DJ, ..., Dong XC, ..., Zughaier SM. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222.
Xiong X, Wang G, Tao R, Wu P, Kono T, Li K, Ding WX, Tong X, Tersey SA, Harris RA, Mirmira RG, Evans-Molina C, Dong XC. Sirtuin 6 regulates glucose-stimulated insulin secretion in mouse pancreatic beta cells. Diabetologia. 2016 Jan;59(1):151-60.
Dong XC. The potential of sestrins as therapeutic targets for diabetes. Expert Opin Ther Targets. 2015 May 5:1-5. [Epub ahead of print]
Tao R, Xiong X, Liangpunsakul S, Dong XC. Sestrin 3 Protein Enhances Hepatic Insulin Sensitivity by Direct Activation of the mTORC2-Akt Signaling. Diabetes 2014 Nov 5 [Epub ahead of print]
Kang X, Petyaykina K, Tao R, Xiong X, Dong XC, Liangpunsakul S. The inhibitory effect of ethanol on Sestrin3 in the pathogenesis of ethanol-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2014 Jul 1;307(1):G58-65.
Sadagurski M*, Dong XC*, Myers MG, White MF. Irs2 and Irs4 synergize in non-LepRb neurons to control energy balance and glucose homeostasis. Mol Metab. 2013 Oct. 25. [Epub ahead of print], * Co-first authors.
He G, Zhang YW, Lee JH, Zeng SX, Wang YV, Luo Z, Dong XC, Viollet B, Wahl GG, Lu H. AMP-Activated Protein Kinase Induces p53 by Phosphorylating MDMX and Inhibiting Its Activity. Mol Cell Biol. 2014 Jan;34(2):148-57.
Riehle C, Wende AR, Sena S, Pires KM, Pereira RO, Zhu Y, Bugger H, Frank D, Bevins J, Chen D, Perry CN, Dong XC, Valdez S, Rech M, Sheng X, Weimer BC, Gottlieb RA, White MF, Abel ED. Insulin receptor substrate signaling suppresses neonatal autophagy in the heart. J Clin Invest. 2013 Dec 2;123(12):5319-33.
Tao R, Xiong X, Depinho RA, Deng CX, Dong XC. FoxO3 transcription factor and Sirt6 deacetylase regulate LDL-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem. 2013 Aug 23. [Epub ahead of print]
Xiong X, Tao R, Depinho RA, Dong XC. Deletion of Hepatic FoxO1/3/4 Genes in Mice Significantly Impacts on Glucose Metabolism through Downregulation of Gluconeogenesis and Upregulation of Glycolysis. PLoS One. 2013 Aug 28;8(8):e74340.
Tao R, Xiong X, Harris RA, White MF, Dong XC. Genetic inactivation of pyruvate dehydrogenase kinases improves hepatic insulin resistance induced diabetes. PLoS One. 2013 Aug 5;8(8):e71997.
Tao R, Xiong X, Depinho RA, Deng CX, Dong XC. Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6. J Lipid Res. 2013 Jul 23. [Epub ahead of print]
Lin CW, Zhang H, Li M, Xiong X, Chen X, Chen X, Dong XC, Yin XM. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol. 2013; 58(5):993-9. PMCID: PMC3634371
Dhurandhar EJ, Krishnapuram R, Hegde V, Dubuisson O, Tao R, Dong XC, Ye J, Dhurandhar NV. E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia. PLoS One 2012; 7(10):e47813. PMCID: PMC3479113
Zhang S, Liu S, Tao R, Wei D, Chen L;, Shen W, Yu Z, Wang L, Dong XC, Zhang ZY. A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes. J Am Chem Soc. 2012; 134(43):18116-24. PMCID: PMC3505080
Xiong X, Tao R, DePinho RA, Dong XC. The autophagy-related gene 14 (Atg14) is regulated by forkhead box O transcription factors and circadian rhythms and plays a critical role in hepatic autophagy and lipid metabolism. J. Biol. Chem. 2012; 287(46):39107-14. PMCID: PMC3493951
Dong XC. Sirtuin biology and relevance to diabetes treatment. Diabetes Management 2012; 2(3):243-257. PMCID: PMC3458714
Sadagurski M, Cheng Z, Rozzo A, Palazzolo I, Kelley GR, Dong X, Krainc D, White MF. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J Clin Invest. 2011;121(10):4070-81. PMCID: PMC3195462
Tao R, Wei D, Gao H, Liu Y, DePinho RA, Dong XC. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J. Biol. Chem. 2011; 286(16):14681-90. PMCID: PMC3077665
Wei D, Tao R, Zhang Y, White MF, Dong XC. Feedback regulation of hepatic gluconeogenesis through modulation of SHP/Nr0b2 gene expression by Sirt1 and FoxO1. Am J Physiol Endocrinol Metab. 2011;300(2):E312-20. PMCID: PMC3043623
Cheng Z, Guo S, Copps K, Dong X, Kollipara R, Rodgers JT, Depinho RA, Puigserver P, White MF. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med. 2009;15(11):1307-11
Guo S, Copps KD, Dong X, Park S, Cheng Z, Pocai A, Rossetti L, Sajan M, Farese RV, White MF. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol. 2009; 29(18):5070-83. PMCID: PMC2738277
Dong, XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White MF. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 2008; 8(1): 65-76. PMCID: PMC2929667
Li D, Yin X, Zmuda EJ, Wolford CC, Dong X, White MF, Hai T. The repression of IRS2 gene by ATF3, a stress-inducible gene, contributes to pancreatic beta-cell apoptosis. Diabetes 2008; 57(3): 635-644.
Giraud J, Haas M, Feener EP, Copps KD, Dong X, Dunn SL, White MF. Phosphorylation of Irs1 at SER-522 inhibits insulin signaling. Mol. Endocrinol. 2007; 21(9): 2294-2302.
Dong X, Park S, Lin X, Copps K, Yi X, and White MF. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J. Clin. Invest. 2006; 116(1): 101-114. PMCID: PMC1319221
Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G, and White MF. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 2006; 281(2): 1159-1168
Diabetes and obesity have both reached epidemic proportions in the United States. It is becoming urgent to elucidate the pathological mechanisms of these health problems. Improper gene regulation by transcriptional and epigenetic factors critically involves in the pathogenesis of these metabolic diseases. My laboratory investigates two key families of factors that are emerging as critical regulators in nutrient and energy homeostasis - FOXO transcription factors and nuclear sirtuins (SIRT1/6). FOXOs are key players in the downstream of insulin signaling and regulate glucose and lipid homeostasis. SIRT1 and SIRT6 are both NAD-dependent histone deacetylases and modulate chromatin stability and dynamics. We have characterized several crucial FOXO target genes including Nr0b2 (SHP), Nampt, Srebp2, Pcsk9, and Sesn3, in the regulation of glucose and lipid metabolism and insulin sensitivity. Our research goal is to utilize the state-of-the-art technologies including genomics, epigenomics, proteomics, metabolomics, high-resolution imaging, and genomic editing to elucidate molecular and pathophysiological mechanisms underlying diabetes, obesity, and fatty liver disease and develop therapeutics for these disorders.